Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025

Overview

Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025 presents comprehensive updates on the latest advances in the diagnosis and treatment of hematologic malignancies. This educational activity covers new data from the American Society of Hematology (ASH) Annual Meeting, focusing on emerging therapies relevant to clinical practice.

On-demand Oncology & Hematology education — accessible anytime, anywhere.

Agenda

This on-demand course delivers focused lectures on cutting-edge therapeutic advances from the 2024 ASH Annual Meeting, designed to strengthen clinical knowledge and guide treatment decisions in blood cancers.

• Welcome and Introduction — Ann S. LaCasce, MD
• ASH 2024: Transplant Highlights — Mahasweta Gooptu, MD
• ASH 2024: ALL, CML and MPNs Highlights — Daniel DeAngelo, MD, PhD
• ASH 2024: Classical Hematology Highlights — Nathan T. Connell, MD, MPH
• ASH 2024: MDS and AML — Richard M. Stone, MD
• 15-minute Break
• ASH 2024: CLL Highlights — Inhye E. Ahn, MD
• ASH 2024: Multiple Myeloma Highlights — Shonali Midha, MD
• ASH 2024: Lymphoma Highlights — Jennifer L. Crombie, MD
• ASH 2024: CAR-T Highlights — Caron A. Jacobson, MD
• Closing Remarks — Ann S. LaCasce, MD

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe an overview and highlight recent medical advances presented at the ASH Annual Meeting to support better patient management.
• Recognize appropriate management and treatment options for hematologic malignancies.
• Utilize these emerging therapeutic approaches in routine clinical practice.
• Review new therapies and approaches in non-malignant hematology.

Speakers

• Ann S. LaCasce, MD
• Mahasweta Gooptu, MD
• Daniel DeAngelo, MD, PhD
• Nathan T. Connell, MD, MPH
• Richard M. Stone, MD
• Inhye E. Ahn, MD
• Shonali Midha, MD
• Jennifer L. Crombie, MD
• Caron A. Jacobson, MD

Target Audience

This activity is intended for hematologists, oncologists, oncology and hematology physicians and trainees, primary care physicians, nurses, physician assistants, and nurse practitioners involved in the care of patients with hematologic diseases.

Why This Topic Matters

Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025 provides critical updates in hematology-oncology that inform clinical decision-making for blood cancers. It addresses the need for clinicians to access new data from key research presented at the ASH Annual Meeting, which impacts patient management strategies.

This content strengthens professional expertise in a complex and evolving specialty, enabling practitioners to stay current with advances in hematologic malignancies through MedHub Central’s on-demand platform.